NCT00418730

Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss

A Phase 2 Multicenter, Randomized, Placebo- and Comparator-Controlled, Double-Blind Parallel Group Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopecia in Men

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 180 (actual)
• Sponsor: Neosil, Inc. · Industry
• Sex: Male
• Age: 18 Years – 49 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to measure the hair growth response to topical NEOSH101 when applied twice daily to the balding scalp for 16 weeks. One hundred eighty men with Norwood/Hamilton grades III-IV with thinning in the top and center of the scalp will participate. Three equally sized treatment groups (60 men each) will receive either topical NEOSH101 2.0%, minoxidil 5%, or placebo.

Conditions

• Androgenetic Alopecia

Interventions

Type	Name	Description
DRUG	tetrapeptide aldehyde proteasome inhibitor (NEOSH101)	Study preparation (experimental, active comparator, placebo comparator) will be applied twice daily to the scalp for 112 days

Timeline

• Start date: 2007-01-01
• Primary completion: 2007-10-01
• Completion: 2008-04-01
• First posted: 2007-01-05
• Last updated: 2008-05-20

Locations

1 site across 1 country: Germany